UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): September 7, 2023
PALATIN TECHNOLOGIES, INC. |
(Exact name of registrant as specified in its charter) |
Delaware |
|
001-15543 |
|
95-4078884 |
(State or other jurisdiction |
|
(Commission |
|
(IRS employer |
of incorporation) |
|
File Number) |
|
identification number) |
4B Cedar Brook Drive, Cranbury, NJ |
|
08512 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant's telephone number, including area code: (609) 495-2200
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered |
Common Stock |
|
PTN |
|
NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On September 7, 2023, Palatin Technologies, Inc. issued a press release announcing that the company will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY. A copy of this press release is attached as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
|
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PALATIN TECHNOLOGIES, INC. |
|
|
|
|
|
|
Date: September 8, 2023 |
By: |
/s/ Stephen T. Wills |
|
|
|
Stephen T. Wills, CPA, MST |
|
|
|
Executive Vice President, Chief Financial Officer and Chief Operating Officer |
|
3 |
EXHIBIT INDEX
|
4 |
EXHIBIT 99.1
Palatin to Present at the H.C. Wainwright
25th Annual Global Investment Conference
Cranbury, NJ, September 7, 2023 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY.
The Company presentation will be held on Wednesday, September 13, 2023 at 10:00 a.m. ET. A live webcast of the presentation will be available on the Investors section of Palatin’s website at http://www.palatin.com. A replay of the webcast will be available for 30 days following the presentation.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
Investor Inquiries: | Media Inquiries: |
Stephen T. Wills, CPA, MST | Paul Arndt, MBA, LifeSci Advisors |
CFO/COO (609) 495-2200 | Managing Director (646) 597-6992 |
Info@Palatin.com | Paul@LifeSciAdvisors.com |
###